{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nerve+Sheath+Neoplasm&page=4", "query": { "condition": "Nerve Sheath Neoplasm", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 288, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nerve+Sheath+Neoplasm&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nerve+Sheath+Neoplasm&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T11:45:13.718Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02008877", "title": "SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Peripheral Nerve Sheath Tumors (MPNST)", "Sarcoma" ], "interventions": [ { "name": "ganetespib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Alliance for Research through Collaboration", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 20, "start_date": "2013-12", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2019-05-15", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 7, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02008877" }, { "nct_id": "NCT02944032", "title": "Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neurofibromatosis Type 1" ], "interventions": [ { "name": "CogmedRM", "type": "OTHER" }, { "name": "Mobymax", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Kristina Hardy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "8 Years to 16 Years" }, "enrollment_count": 103, "start_date": "2016-05", "completion_date": "2021-09-27", "has_results": false, "last_update_posted_date": "2022-03-03", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02944032" }, { "nct_id": "NCT01880749", "title": "Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Neurofibromatosis Type 2", "Vestibular Schwannomas", "Meningiomas" ], "interventions": [ { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-06", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01880749" }, { "nct_id": "NCT01154452", "title": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Alveolar Soft Part Sarcoma", "Adult Angiosarcoma", "Adult Desmoplastic Small Round Cell Tumor", "Adult Epithelioid Hemangioendothelioma", "Adult Epithelioid Sarcoma", "Adult Extraskeletal Myxoid Chondrosarcoma", "Adult Extraskeletal Osteosarcoma", "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Mesenchymoma", "Adult Malignant Peripheral Nerve Sheath Tumor", "Adult Rhabdomyosarcoma", "Adult Synovial Sarcoma", "Adult Unclassified Pleomorphic Sarcoma", "Chondrosarcoma", "Clear Cell Sarcoma of the Kidney", "Conjunctival Kaposi Sarcoma", "Dermatofibrosarcoma Protuberans", "Gastrointestinal Stromal Tumor", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Metastatic Osteosarcoma", "Ovarian Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Kaposi Sarcoma", "Recurrent Osteosarcoma", "Recurrent Uterine Corpus Sarcoma", "Small Intestine Leiomyosarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Uterine Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Uterine Sarcoma", "Unclassified Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2010-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-08-15", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154452" }, { "nct_id": "NCT00931931", "title": "HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rhabdomyosarcoma", "Osteosarcoma", "Ewing Sarcoma", "Soft Tissue Sarcoma", "Neuroblastoma", "Wilms Tumor", "Malignant Peripheral Nerve Sheath Tumor", "Clival Chordoma", "Non-CNS Solid Tumors" ], "interventions": [ { "name": "HSV1716", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Timothy Cripe", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "7 Years to 30 Years" }, "enrollment_count": 18, "start_date": "2010-03", "completion_date": "2018-03-19", "has_results": false, "last_update_posted_date": "2018-03-21", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00931931" }, { "nct_id": "NCT05253131", "title": "Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MPNST", "NF1", "Sarcoma" ], "interventions": [ { "name": "Selumetinib + ZEN-3694 ± Durvalumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 41, "start_date": "2026-08-04", "completion_date": "2032-11-15", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05253131" }, { "nct_id": "NCT04872543", "title": "A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Peripheral Nerve Sheath Tumors (MPNST)" ], "interventions": [ { "name": "ASTX727", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 25, "start_date": "2021-04-29", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872543" }, { "nct_id": "NCT06502171", "title": "Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis 1", "Plexiform Neurofibroma" ], "interventions": [ { "name": "Cabozantinib Oral Tablet", "type": "DRUG" }, { "name": "Selumetinib Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Girish Dhall, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 30, "start_date": "2026-06-09", "completion_date": "2034-08-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06502171" }, { "nct_id": "NCT04481048", "title": "Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neurofibromatosis 1" ], "interventions": [ { "name": "N-Acetyl cysteine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "8 Years to 16 Years" }, "enrollment_count": 25, "start_date": "2021-02-23", "completion_date": "2024-06-25", "has_results": true, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04481048" }, { "nct_id": "NCT05521048", "title": "Doxycycline in Cutaneous Schwannoma (NF2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neurofibromatosis Type 2" ], "interventions": [ { "name": "Doxycycline Injection [Doxy]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 19, "start_date": "2022-09-19", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-10-07T11:45:13.718Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05521048" } ] }